Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB
Mandate

Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB

November 29, 2021 Employment and Benefits Commercial Agreements Intellectual Property IT, Telecommunications and Outsourcing M&A

Established in 2015, with headquarters in Stockholm, Spendency has grown into a leading spend analytics provider.

Connected directly to the clients’ ERP and/or procurement system, Spendency helps its customers to collect, enrich and normalise supplier data. Spendency serves a vast customer base of more than 100 customers and over 1,500 users. Through the acquisition, Onventis strategically expands its product offering within spend analytics.

Vinge’s team consisted of Filip Öhrner and Eléonore Friberg (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (Agreements), Karolina Fuhrman (GDPR/IT), Arvid Axelryd (IP) and Jessica Henning (VDR).

 

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

 Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026